Refine
Year of publication
Document Type
- Preprint (692)
- Article (508)
- Conference Proceeding (3)
- Working Paper (1)
Has Fulltext
- yes (1204)
Is part of the Bibliography
- no (1204)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- HIV (5)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- breast cancer (4)
- ALICE (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- coronavirus (3)
- pp collisions (3)
- Beauty production (2)
- Breast cancer (2)
- COVID-19 (2)
- CRM (2)
- Charm physics (2)
- Diagnostik (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Früherkennung (2)
- Heavy Quark Production (2)
- Hepatitis C virus (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Relativistic heavy-ion collisions (2)
- Richtlinie (2)
- Single electrons (2)
- biomarker (2)
- brain metastases (2)
- cirrhosis (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- guidelines (2)
- reference values (2)
- screening (2)
- stroke (2)
- 900 GeV (1)
- AA-amylodosis (1)
- ABC transporters (1)
- ACLF (1)
- ADHD (1)
- ALICE detector (1)
- APRI (1)
- ASAP (1)
- ATAD2 (1)
- ATPases (1)
- Abrasion (1)
- Adverse events (1)
- Alien (1)
- Alternating Phase Focusing (1)
- Anti-nuclei (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Artesunate (1)
- Atmospheric science (1)
- B cell subpopulations (1)
- BRCA1 (1)
- BRCA2 (1)
- BRD2 (1)
- BRD4 (1)
- BROMO-10 (1)
- Baryonic resonances (1)
- Beam dynamics simulation (1)
- Big Five (1)
- Biodiversity (1)
- Biogeographical representativeness (1)
- Boosted Jets (1)
- CD16 (1)
- CD56 (1)
- CDH13 (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- CVID (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer genomics (1)
- Central nervous system metastases (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Chemoradiotherapy (1)
- Chemorefractory advanced gastric cancer (1)
- Child (1)
- Child abuse (1)
- Children (1)
- Chronic kidney disease (1)
- Cirrhosis (1)
- Claims on land (1)
- Climate change (1)
- Clinical genetics (1)
- Clinical study (1)
- Clinical variation (1)
- Collective Flow, (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Consensus (1)
- Continuous wave (1)
- Cytoskeleton (1)
- Data management (1)
- Decision trees (1)
- Decontamination (1)
- Dental air (1)
- Dental implants (1)
- Depression (1)
- Dermatomyositis (1)
- Devic disease (1)
- Devic syndrome (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Docetaxel (1)
- Drug therapy (1)
- EBV (1)
- Ecosystem integrity (1)
- Ecosystem services (1)
- Ecosystems (1)
- Elderly (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Emotions (1)
- Entomology (1)
- Environment (1)
- Ephrin-B2–EphB4 (1)
- Essential biodiversity variables (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exosomes (1)
- Experimental models of disease (1)
- FIB-4 (1)
- FOLFIRI (1)
- FXIII deficiency (1)
- Factor XIII (1)
- Falciparum (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- First site of metastatic disease (1)
- First-line combination antiretroviral therapy (1)
- Forensic examination (1)
- Forschung (1)
- Frailty (1)
- Freezeout (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- General practitioners (1)
- Genetics research (1)
- Genomic instability (1)
- German PID-NET registry (1)
- Gleason Score (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (1)
- HIV-1 (1)
- HIV-RNA (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Heavy-ion reactions (1)
- Hepatotoxicity (1)
- Hereditary breast and ovarian cancer (1)
- Human behaviour (1)
- Human well-being (1)
- Hyperons (1)
- Hypertension (1)
- IHC (1)
- IVDU (1)
- IgG substitution therapy (1)
- Immunology (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Inverse kinematics (1)
- Ionisation energy loss (1)
- Isoscalar giant resonances (1)
- Jet Physics (1)
- Jet Substructure (1)
- LTER (1)
- Lehre (1)
- Linear accelerator (1)
- Liver diseases (1)
- Liver enzymes (1)
- Liver transplantation (1)
- Long-term ecological monitoring (1)
- Long‐term ecosystem research (1)
- MRI (1)
- MS (1)
- Malaria (1)
- Material budget (1)
- Mental health and psychiatry (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Molecular medicine (1)
- Molecular neuroscience (1)
- Mongolian spot (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multivariate analysis (1)
- Myanmar (1)
- NK cells (1)
- NMO-IgG (1)
- NSAIDs (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant therapy (1)
- Neural network (1)
- Neuromyelitis optica (1)
- Nevus of Ito (1)
- Nevus of Ota (1)
- Noninferiority (1)
- Nonlinear beam dynamics (1)
- Nuclear modification factor (1)
- Nucleus (1)
- ORL (1)
- Observation (1)
- Oesophagogastric cancer oxaliplatin (1)
- Oldest-old (1)
- Osteoporosis (1)
- Otorhinolaryngology (1)
- PID prevalence (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pathological complete response (1)
- Pb–Pb (1)
- Peri-implantitis (1)
- Personalized medicine (1)
- Phylogenomics (1)
- Physiology (1)
- Plasmodium (1)
- Population genetics (1)
- Pre-treatment drug resistance mutations (1)
- Predictive markers (1)
- Predictive medicine (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- Psychometrics (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Questionnaires (1)
- Quinine (1)
- Rapidity Range (1)
- Regression analysis (1)
- Relativistic heavy ion physics (1)
- Renal lesions (1)
- Research (1)
- Research infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Rheumatoid arthritis (1)
- Rheumatology (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SF-36 (1)
- Severe malaria (1)
- Single muons (1)
- Site networks (1)
- Socio-ecology (1)
- Specialist training (1)
- Stentoplasty (1)
- Storage ring (1)
- Strangeness (1)
- Sunitinib (1)
- Sustainability (1)
- Systematic Uncertainty (1)
- T-DM1 (1)
- TR (1)
- Teaching (1)
- Thrombosis (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Triple negative (1)
- Triple-negative breast cancer (1)
- Tyrosine kinase inhibitor (1)
- University hospitals (1)
- Universitätskliniken (1)
- VEGF (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Viral load (1)
- Virological failure (1)
- WHO-5 (1)
- Weiterbildung (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- acoustic radiation force impulse imaging (1)
- acute-on-chronic liver failure (1)
- acute‐on‐chronic liver failure (1)
- advanced breast cancer (1)
- agreeableness (1)
- allogeneic transplantation (1)
- androgen receptor (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- anti-retroviral agents (1)
- antibiotic resistance (1)
- antibiotics (1)
- antihormone therapy (1)
- aquaporin-4 (AQP4) antibody (1)
- asymptomatic (1)
- autoimmunity (1)
- binary nucleation (1)
- bioprinting (1)
- biosecurity (1)
- blood hiv rna (1)
- body-on-a-chip (1)
- bortezomib (1)
- bromodomain inhibitor (1)
- cART (1)
- cancer therapy (1)
- castration-resistant prostate cancer (1)
- cd4 count determination procedure (1)
- cerebrospinal fluid (1)
- chemotherapy (1)
- children (1)
- chromatin (1)
- circulation (1)
- clinical features (1)
- co-infection (1)
- complement system (1)
- concept (1)
- concordance (1)
- conservation (1)
- cryo-EM (1)
- dE/dx (1)
- detector (1)
- downgrading (1)
- e-Health (1)
- emergency care (1)
- epidemiology (1)
- everolimus (1)
- excipients (1)
- executive functions (1)
- exercise (1)
- exotic (1)
- experimental results (1)
- expertise (1)
- exponential model (1)
- fecal microbiota transfer (1)
- fibrotest (1)
- flow cytometry (1)
- fusion biopsy (1)
- graft-vs-host disease (1)
- health (1)
- heart-on-a-chip (1)
- heavy ion experiments (1)
- hemodynamic (1)
- hepatitis C (1)
- hiv (1)
- hospital admission (1)
- human allogeneic hematopoietic cell transplantation (1)
- human immunodeficiency virus (1)
- human intestinal microbiota (1)
- immune reconstitution (1)
- immunohistochemistry (1)
- impact (1)
- induction regimen (1)
- inflammation (1)
- invasion (1)
- ion‐induced nucleation (1)
- kidney (1)
- kidney-on-a-chip (1)
- lantibiotic (1)
- lapatinib (1)
- lenalidomide (1)
- lipoprotein (1)
- liver-on-a-chip (1)
- lockdowns (1)
- longitudinally extensive transverse myelitis (1)
- lung-on-a-chip (1)
- magnetic resonance imaging (1)
- male (1)
- management (1)
- mass spectrometry (1)
- mechanical ventilation (1)
- membrane proteins (1)
- metastatic (1)
- metastatic renal cell carcinoma (1)
- micro-physiological systems (1)
- molecular machines (1)
- mortality (1)
- multiple myeloma (1)
- native (1)
- neurodevelopment (1)
- nisin binding (1)
- non-invasive fibrosis assessment (1)
- nonnative (1)
- nuclear magnetic resonance (NMR) (1)
- organs-on-a-chip (1)
- pain (1)
- pertuzumab (1)
- phase IV (1)
- phylogeny (1)
- physical activity (1)
- pleiotropy (1)
- pneumocystis carinii (1)
- pneumocystis pneumonia (1)
- pneumonia (1)
- point shear wave elastography (1)
- prevention (1)
- primary active transporters (1)
- primary immunodeficiency (PID) (1)
- prognostic scores (1)
- prophylaxis (1)
- prostate cancer (1)
- prostate neoplasm (1)
- protein structure (1)
- psychological health (1)
- pulmonary failure (1)
- quark gluon plasma (1)
- radical prostatectomy (1)
- recurrent optic neuritis (1)
- registry for primary immunodeficiency (1)
- renal failure (1)
- respiratory failure (1)
- risk (1)
- second-line (1)
- seed and soil (1)
- sequence alignment (1)
- simulation (1)
- simulation training (1)
- skin-on-a-chip (1)
- small angle x-ray scattering (1)
- spectra (1)
- sphingolipid (1)
- spinal bone metastasis (1)
- stakeholder (1)
- structural biology (1)
- systematic biopsy (1)
- telemedicine (1)
- thrombolysis (1)
- thrombolysis (tPA) (1)
- training (1)
- transient elastography (1)
- trastuzumab (1)
- uncertainty (1)
- upgrading (1)
- valuation (1)
- working memory (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1092)
- Frankfurt Institute for Advanced Studies (FIAS) (961)
- Informatik (924)
- Medizin (72)
- Geowissenschaften (12)
- Biochemie und Chemie (7)
- Biowissenschaften (5)
- Institut für Ökologie, Evolution und Diversität (4)
- ELEMENTS (3)
- Informatik und Mathematik (3)
The 23Al(p, γ)24Si stellar reaction rate has a significant impact on the light-curve emitted in X-ray bursts. Theoretical calculations show that the reaction rate is mainly determined by the properties of direct capture as well as low-lying 2+ states and a possible 4+ state in 24Si. Currently, there is little experimental information on the properties of these states.
In this proceeding we will present a new experimental study to investigate this reaction, using the surrogate reaction 23Al(d,n) at 47 AMeV at the National Superconducting Cyclotron Laboratory (NSCL). We will discuss our new experimental setup which allows us to use full kinematics employing the Gamma-Ray Energy Tracking In-beam Nuclear Array (GRETINA) to detect the γ-rays following the de-excitation of excited states of the reaction products and the Low Energy Neutron Detector Array (LENDA) to detect the recoiling neutrons. The S800 was used for identification of the 24Si recoils. As a proof of principle to show the feasibility of this concept the Q-value spectrum of 22Mg(d,n)23Al is reconstructed.
Darstellung und Eigenschaften des Coenzymanalogen Nicotinamid-4-methyl-5-acetyl-imidazol-dinucleotid
(1970)
Kondensation des Quecksilbersalzes von 4-Methyl-5-acetyl-imidazol ** mit 1-Chlor-2.3.5-O-tribenzoyl-ribofuranose liefert das geschützte Ribosid 3. Zur Strukturaufklärung der Verbindung wurde 4-Methyl-5-acetyl-1-(β-D-0-2′.3′.5′-triacetyl-ribofuranosyl)-imidazol mit Methyljodid in das 3.4-Dimethyl-5-acetyl-1-(β-D-O-2′.3′.5′-triacetyl-ribofuranosyl)-imidazoliumjodid überführt und der Zuckerrest hydrolytisch gespalten. Das entstandene Imidazol-Derivat ist identisch mit 1.5-Dimethyl-4-acetyl-imidazol. 4-Methyl-5-acetyl-1- (β-D-ribofuranosyl) -imidazol wurde mit Aceton in das Isopropyliden-Derivat 4 überführt. Die Phosphorylierung zum Nucleosid-5′-phosphat (5) führten wir mit β-Cyanäthyl-phosphat durch. Durch Kondensation mit Nicotinamid-mononucleotid erhielten wir das Coenzymanaloge Nicotinamid-4-methyl-5-acetyl-imidazol-dinucleotid (6). Die Verbindung liegt im oxydierten Zustand in gefaltener Form vor. Das Fluoreszenz-Anregungsspektrum der Dihydroverbindung zeigt keine Energieübertragung vom nichtfunktionellen 4-Methyl-5-acetyl-imidazol-Teil auf den Dihydronicotinamid-Ring. Das Coenzymanaloge weist eine größere Michaelis- Konstante im Test mit Lactat-Dehydrogenase aus Schweineherz *** auf als das natürliche Nicotinamid-adenindinucleotid ***. Die maximale Umsatzzahl ist trotz der schwächeren Bindung vergrößert. Das unterschiedliche Verhalten des Coenzymanalogen 6 gegenüber NAD läßt, neben der π-Bindung des nichtfunktionellen Teils, eine polare Gruppe im aktiven Zentrum des Enzyms vermuten, die die Ausrichtung des Coenzyms im Coenzym-Enzym-Komplex bewirkt.
Dihydronicotinamid-4-methyl-5-acetyl-imidazol-dinucleotid bildet einen fluoreszierenden Komplex mit der Lactat-Dehydrogenase, der dem des NADH-LDH-Komplexes sehr ähnlich ist.
Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. Results: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7–10. Conclusions: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa.
Background: The impact of MRI-lesion targeted (TB) and systematic biopsy (SB) Gleason score (GS) as a predictor for final pathological GS still remains unclear. Methods: All patients with TB + SB, and subsequent radical prostatectomy (RP) between 01/2014-12/2020 were analyzed. Rank correlation coefficient predicted concordance with pathological GS for patients’ TB and SB GS, as well as for the combined effect of SB + TB. Results: Of 159 eligible patients, 77% were biopsy naïve. For SB taken in addition to TB, a Spearman’s correlation of +0.33 was observed regarding final GS. Rates of concordance, upgrading, and downgrading were 37.1, 37.1 and 25.8%, respectively. For TB, a +0.52 correlation was computed regarding final GS. Rates of concordance, upgrading and downgrading for TB biopsy GS were 45.9, 33.3, and 20.8%, respectively. For the combination of SB + TB, a correlation of +0.59 was observed. Rates of concordance, upgrading and downgrading were 49.7, 15.1 and 35.2%, respectively. The combined effect of SB + TB resulted in a lower upgrading rate, relative to TB and SB (both p < 0.001), but a higher downgrading rate, relative to TB (p < 0.01). Conclusions: GS obtained from TB provided higher concordance and lower upgrading and downgrading rates, relative to SB GS with regard to final pathology. The combined effect of SB + TB led to the highest concordance rate and the lowest upgrading rate.
Members of the ATP‐binding cassette (ABC) transporter superfamily translocate a broad spectrum of chemically diverse substrates. While their eponymous ATP‐binding cassette in the nucleotide‐binding domains (NBDs) is highly conserved, their transmembrane domains (TMDs) forming the translocation pathway exhibit distinct folds and topologies, suggesting that during evolution the ancient motor domains were combined with different transmembrane mechanical systems to orchestrate a variety of cellular processes. In recent years, it has become increasingly evident that the distinct TMD folds are best suited to categorize the multitude of ABC transporters. We therefore propose a new ABC transporter classification that is based on structural homology in the TMDs:
Background: Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.
Methods: HIV-infected children <18 years initiating cART between 1998 and 2008 were included if having at least one genotypic resistance test prior to cART initiation. We used the World Health Organization 2009 resistance mutation list and Stanford algorithm to infer resistance to prescribed drugs. Time to virological failure (VF) was defined as the first of two consecutive HIV-RNA > 500 copies/mL after 6 months cART and was assessed by Cox proportional hazards models. All models were adjusted for baseline demographic, clinical, immunology and virology characteristics and calendar period of cART start and initial cART regimen.
Results: Of 476 children, 88 % were vertically infected. At cART initiation, median (interquartile range) age was 6.6 years (2.1–10.1), CD4 cell count 297 cells/mm3 (98–639), and HIV-RNA 5.2 log10copies/mL (4.7–5.7). Of 37 children (7.8 %, 95 % confidence interval (CI), 5.5–10.6) harboring a virus with ≥1 PDR mutations, 30 children had a virus resistant to ≥1 of the prescribed drugs. Overall, the cumulative Kaplan-Meier estimate for virological failure was 19.8 % (95 %CI, 16.4–23.9). Cumulative risk for VF tended to be higher among children harboring a virus with PDR and resistant to ≥1 drug prescribed than among those receiving fully active cART: 32.1 % (17.2–54.8) versus 19.4 % (15.9–23.6) (P = 0.095). In multivariable analysis, age was associated with a higher risk of VF with a 12 % reduced risk per additional year (HR 0.88; 95 %CI, 0.82–0.95; P < 0.001).
Conclusions: PDR was not significantly associated with a higher risk of VF in children in the first year of cART. The risk of VF decreased by 12 % per additional year at treatment initiation which may be due to fading of PDR mutations over time. Lack of appropriate formulations, in particular for the younger age group, may be an important determinant of virological failure.
Background: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy in childhood and a major cause of morbidity among children with pediatric rheumatic diseases. The management of JDM is very heterogeneous. The JDM working group of the Society for Pediatric Rheumatology (GKJR) aims to define consensus- and practice-based strategies in order to harmonize diagnosis, treatment and monitoring of JDM.
Methods: The JDM working group was established in 2015 consisting of 23 pediatric rheumatologists, pediatric neurologists and dermatologists with expertise in the management of JDM. Current practice patterns of management in JDM had previously been identified via an online survey among pediatric rheumatologists and neurologists. Using a consensus process consisting of online surveys and a face-to-face consensus conference statements were defined regarding the diagnosis, treatment and monitoring of JDM. During the conference consensus was achieved via nominal group technique. Voting took place using an electronic audience response system, and at least 80% consensus was required for individual statements.
Results: Overall 10 individual statements were developed, finally reaching a consensus of 92 to 100% regarding (1) establishing a diagnosis, (2) case definitions for the application of the strategies (moderate and severe JDM), (3) initial diagnostic testing, (4) monitoring and documentation, (5) treatment targets within the context of a treat-to-target strategy, (6) supportive therapies, (7) explicit definition of a treat-to-target strategy, (8) various glucocorticoid regimens, including intermittent intravenous methylprednisolone pulse and high-dose oral glucocorticoid therapies with tapering, (9) initial glucocorticoid-sparing therapy and (10) management of refractory disease.
Conclusion: Using a consensus process among JDM experts, statements regarding the management of JDM were defined. These statements and the strategies aid in the management of patients with moderate and severe JDM.
The single nucleotide polymorphism 118A>G of the human micro-opioid receptor gene OPRM1, which leads to an exchange of the amino acid asparagine (N) to aspartic acid (D) at position 40 of the extracellular receptor region, alters the in vivo effects of opioids to different degrees in pain-processing brain regions. The most pronounced N40D effects were found in brain regions involved in the sensory processing of pain intensity. Using the mu-opioid receptor-specific agonist DAMGO, we analyzed the micro-opioid receptor signaling, expression, and binding affinity in human brain tissue sampled postmortem from the secondary somatosensory area (SII) and from the ventral posterior part of the lateral thalamus, two regions involved in the sensory processing and transmission of nociceptive information. We show that the main effect of the N40D micro-opioid receptor variant is a reduction of the agonist-induced receptor signaling efficacy. In the SII region of homo- and heterozygous carriers of the variant 118G allele (n=18), DAMGO was only 62% as efficient (p=0.002) as in homozygous carriers of the wild-type 118A allele (n=15). In contrast, the number of [3H]DAMGO binding sites was unaffected. Hence, the micro-opioid receptor G-protein coupling efficacy in SII of carriers of the 118G variant was only 58% as efficient as in homozygous carriers of the 118A allele (p<0.001). The thalamus was unaffected by the OPRM1 118A>G SNP. In conclusion, we provide a molecular basis for the reduced clinical effects of opioid analgesics in carriers of mu-opioid receptor variant N40D.
The Coulomb Dissociation (CD) cross sections of the stable isotopes 92,94,100Mo and of the unstable isotope 93Mo were measured at the LAND/R3B setup at GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt, Germany. Experimental data on these isotopes may help to explain the problem of the underproduction of 92,94Mo and 96,98Ru in the models of p-process nucleosynthesis. The CD cross sections obtained for the stable Mo isotopes are in good agreement with experiments performed with real photons, thus validating the method of Coulomb Dissociation. The result for the reaction 93Mo(γ,n) is especially important since the corresponding cross section has not been measured before. A preliminary integral Coulomb Dissociation cross section of the 94Mo(γ,n) reaction is presented. Further analysis will complete the experimental database for the (γ,n) production chain of the p-isotopes of molybdenum.
Microangiopathy with subsequent organ damage represents a major complication in several diseases. The mechanisms leading to microvascular occlusion include von Willebrand factor (VWF), notably the formation of ultra-large von Willebrand factor fibers (ULVWFs) and platelet aggregation. To date, the contribution of erythrocytes to vascular occlusion is incompletely clarified. We investigated the platelet-independent interaction between stressed erythrocytes and ULVWFs and its consequences for microcirculation and organ function under dynamic conditions. In response to shear stress, erythrocytes interacted strongly with VWF to initiate the formation of ULVWF/erythrocyte aggregates via the binding of Annexin V to the VWF A1 domain. VWF-erythrocyte adhesion was attenuated by heparin and the VWF-specific protease ADAMTS13. In an in vivo model of renal ischemia/reperfusion injury, erythrocytes adhered to capillaries of wild-type but not VWF-deficient mice and later resulted in less renal damage. In vivo imaging in mice confirmed the adhesion of stressed erythrocytes to the vessel wall. Moreover, enhanced eryptosis rates and increased VWF binding were detected in blood samples from patients with chronic renal failure. Our study demonstrates that stressed erythrocytes have a pronounced binding affinity to ULVWFs. The discovered mechanisms suggest that erythrocytes are essential for the pathogenesis of microangiopathies and renal damage by actively binding to ULVWFs.